Morgan Stanley began research coverage on Vertex Pharmaceuticals, raising its target price and giving it an overweight rating, alongside institutional filings.
2 reports, 1 independent
Updated Sep 13
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley began research coverage on Vertex Pharmaceuticals, raising its target price and giving it an overweight rating, alongside institutional filings.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.RBC boosted target price on Vertex shares, following MS initiating coverage.1 source
Morgan Stanley raised its target price and gave an overweight rating to Vertex Pharmaceuticals.1 source
Keep exploring
The entities involved
-
Vertex Pharmaceuticals
American pharmaceutical company
-
SEC
Slovak company
-
Morgan Stanley
U.S. investment bank